Ubamatamab

Ubamatamab (REGN4018) is a human bispecific antibody targeted against Mucin 16 (MUC16) and CD3. Ubamatamab demonstrates potent antitumor activity[1].

Research Areas >> Cancer

Signaling Pathways >> Others >> Others

Ubamatamab（REGN4018；0.1 pM-10 nM；48 小时）诱导人 T 细胞和猕猴 T 细胞杀死 OVCAR-3 细胞 (EC50 值分别为 13.6 pM 和 30.6 pM)[1]。 Cell Viability Assay[1] Cell Line: OVCAR-3 cells Concentration: 0.1 pM-10 nM Incubation Time: 48 hours Result: Induced human T cells and cynomolgus T cells to kill OVCAR-3 cells.

Ubamatamab（REGN4018；0.01-0.5 mg/kg；腹腔注射；第 6、10、13、16 和 21 天）有效抑制腹膜内卵巢肿瘤的生长[1]。 Ubamatamab（REGN4018；0.01-1 mg/kg；i.p；每周一次；总共五剂）显示血清细胞因子和 C 反应蛋白有轻微和短暂的增加，没有明显的毒性[1]。 Animal Model: NOD SCID gamma (NSG) mice injected with OVCAR-3/Luc cells[1] Dosage: 0.01 mg/kg, 0.1 mg/kg, 0.5 mg/kg Administration: i.p; on days 6, 10, 13, 16, and 21 Result: Significantly reduced tumor burden, and did not result in any changes in weight. Animal Model: Cynomolgus monkeys Dosage: 0.01, 0.1, or 1 mg/kg Administration: i.p; once a week; total of five doses Result: Showed minimal and transient increases in serum cytokines and C-reactive protein.

[1]. Alison Crawford, et al. A Mucin 16 bispecific T cell-engaging antibody for the treatment of ovarian cancer. Sci Transl Med. 2019 Jun 19;11(497):eaau7534.